365 related articles for article (PubMed ID: 12649131)
21. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
22. A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.
Kim IS; Park ES; Lim JY; Ki CS; Chi HS
J Korean Med Sci; 2008 Dec; 23(6):1105-8. PubMed ID: 19119459
[TBL] [Abstract][Full Text] [Related]
23. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
[TBL] [Abstract][Full Text] [Related]
24. Molecular insights into Down syndrome-associated leukemia.
Vyas P; Crispino JD
Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
[TBL] [Abstract][Full Text] [Related]
25. Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.
Malinge S; Chlon T; Doré LC; Ketterling RP; Tallman MS; Paietta E; Gamis AS; Taub JW; Chou ST; Weiss MJ; Crispino JD; Figueroa ME
Blood; 2013 Oct; 122(14):e33-43. PubMed ID: 23980066
[TBL] [Abstract][Full Text] [Related]
26. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
[TBL] [Abstract][Full Text] [Related]
27. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
28. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
[TBL] [Abstract][Full Text] [Related]
29. Origins of leukaemia in children with Down syndrome.
Hitzler JK; Zipursky A
Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
[TBL] [Abstract][Full Text] [Related]
30. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S
Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia-related malignancies.
Lalonde E; Rentas S; Wertheim G; Cao K; Surrey LF; Lin F; Zhao X; Obstfeld A; Aplenc R; Luo M; Li MM
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832921
[TBL] [Abstract][Full Text] [Related]
32. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
33. Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.
Tsai MH; Hou JW; Yang CP; Yang PH; Chu SM; Hsu JF; Chiang MC; Huang HR
Indian J Pediatr; 2011 Jul; 78(7):826-32. PubMed ID: 21287369
[TBL] [Abstract][Full Text] [Related]
34. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.
Gurbuxani S; Vyas P; Crispino JD
Blood; 2004 Jan; 103(2):399-406. PubMed ID: 14512321
[TBL] [Abstract][Full Text] [Related]
35. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
Xavier AC; Ge Y; Taub JW
J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
[TBL] [Abstract][Full Text] [Related]
36. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.
Alford KA; Slender A; Vanes L; Li Z; Fisher EM; Nizetic D; Orkin SH; Roberts I; Tybulewicz VL
Blood; 2010 Apr; 115(14):2928-37. PubMed ID: 20154221
[TBL] [Abstract][Full Text] [Related]
37. Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation.
Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
Stem Cell Res; 2023 Jun; 69():103098. PubMed ID: 37084616
[TBL] [Abstract][Full Text] [Related]
38. Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.
Ono R; Hasegawa D; Hirabayashi S; Kamiya T; Yoshida K; Yonekawa S; Ogawa C; Hosoya R; Toki T; Terui K; Ito E; Manabe A
Eur J Pediatr; 2015 Apr; 174(4):525-31. PubMed ID: 25266042
[TBL] [Abstract][Full Text] [Related]
39. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome.
Shimada A; Xu G; Toki T; Kimura H; Hayashi Y; Ito E
Blood; 2004 Jan; 103(1):366. PubMed ID: 14684662
[No Abstract] [Full Text] [Related]
40. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.
Cabelof DC; Patel HV; Chen Q; van Remmen H; Matherly LH; Ge Y; Taub JW
Blood; 2009 Sep; 114(13):2753-63. PubMed ID: 19633202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
